The nation of Zimbabwe has rejected a substantial American healthcare agreement worth $367m (£272m) over five years over the United States' demand for sensitive information.
The decision came to light after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government representative later explained that the United States was seeking health data for scientific study and commercial gain while refused to guarantee the benefits from future vaccines.
"We will now turn to the challenging and unfortunate task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for further dialogue to find a agreement acceptable to both sides so the country's vital HIV programme can proceed.
Broader Implications
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a court blocked a related health funding agreement after legal challenges were filed about the safety of Kenyans' health data.
Since returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump argued its expenditure was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
Based on statements, Sixteen nations in Africa have so far signed these new health pacts, representing over $18.3bn in committed funds.
Details of the Rejected Agreement
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment via US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no equivalent assurance of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our people should a future disease outbreak emerge."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral deals were disrupting frameworks already established through the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to manage future global health emergencies.
"This framework is designed to guarantee that when a nation contributes its information, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how future co-operation might be designed in a way that honours the sovereignty and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but recommended that negotiations must proceed since much of the nation's Aids initiatives were funded by international support.
"In cases where specific concerns exist, such as those involving information security or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," the group commented.
The situation emphasises the continuing debate between receiving vital international aid and protecting a country's data in an ever more data-driven world.